BG107891A - П...п'иди и/или про'...ини и 'яхно'о използван... за пол"-аван... на л...кар''в...но 'р...д''во за л...-...ни... и/или про"илак'ика - Google Patents

П...п'иди и/или про'...ини и 'яхно'о използван... за пол"-аван... на л...кар''в...но 'р...д''во за л...-...ни... и/или про"илак'ика Download PDF

Info

Publication number: BG107891A
Authority: BG; Bulgaria
Prior art keywords: peptides; medicament; residue; preparation; apr
Prior art date: 2000-12-12

Application number

BG107891A

Other languages

Bulgarian (bg)

English (en)

Inventor

Peter Petzelbauer

Original Assignee

Fibrex Medical Research & Development Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-12-12

Filing date

2003-06-09

Publication date

2004-08-31

2003-06-09 Application filed by Fibrex Medical Research & Development Gmbh filed Critical Fibrex Medical Research & Development Gmbh

2004-08-31 Publication of BG107891A publication Critical patent/BG107891A/bg

Links

108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 123
239000003814 drug Substances 0.000 title claims abstract description 84
102000004169 proteins and genes Human genes 0.000 title claims abstract description 71
108090000623 proteins and genes Proteins 0.000 title claims abstract description 71
102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 65
230000001225 therapeutic effect Effects 0.000 title claims abstract description 15
230000000069 prophylactic effect Effects 0.000 title claims abstract description 12
238000004519 manufacturing process Methods 0.000 title description 2
150000001413 amino acids Chemical class 0.000 claims abstract description 25
125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims abstract description 15
125000004432 carbon atom Chemical group C* 0.000 claims abstract description 12
125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims abstract description 11
239000000203 mixture Substances 0.000 claims abstract description 10
150000003839 salts Chemical class 0.000 claims abstract description 10
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims abstract description 8
150000001408 amides Chemical class 0.000 claims abstract description 8
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims abstract description 8
239000001257 hydrogen Substances 0.000 claims abstract description 8
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 8
125000004435 hydrogen atom Chemical class [H]* 0.000 claims abstract description 8
229920006395 saturated elastomer Polymers 0.000 claims abstract description 8
229930195734 saturated hydrocarbon Natural products 0.000 claims abstract description 8
229930195735 unsaturated hydrocarbon Natural products 0.000 claims abstract description 8
238000002360 preparation method Methods 0.000 claims description 44
238000011282 treatment Methods 0.000 claims description 44
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical group CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 24
102000009123 Fibrin Human genes 0.000 claims description 22
229950003499 fibrin Drugs 0.000 claims description 22
108010073385 Fibrin Proteins 0.000 claims description 21
210000004027 cell Anatomy 0.000 claims description 20
239000000126 substance Substances 0.000 claims description 20
206010061218 Inflammation Diseases 0.000 claims description 19
230000004054 inflammatory process Effects 0.000 claims description 19
238000011321 prophylaxis Methods 0.000 claims description 18
229940079593 drug Drugs 0.000 claims description 17
210000002889 endothelial cell Anatomy 0.000 claims description 15
230000002265 prevention Effects 0.000 claims description 14
125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 13
210000004369 blood Anatomy 0.000 claims description 11
239000008280 blood Substances 0.000 claims description 11
210000000056 organ Anatomy 0.000 claims description 11
230000002792 vascular Effects 0.000 claims description 11
206010003210 Arteriosclerosis Diseases 0.000 claims description 9
208000011775 arteriosclerosis disease Diseases 0.000 claims description 9
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
206010063837 Reperfusion injury Diseases 0.000 claims description 7
238000006243 chemical reaction Methods 0.000 claims description 7
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 6
241001465754 Metazoa Species 0.000 claims description 6
MESDJCNHLZBMEP-ZLUOBGJFSA-N Ser-Asp-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O MESDJCNHLZBMEP-ZLUOBGJFSA-N 0.000 claims description 6
125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims description 6
QXHVOUSPVAWEMX-ZLUOBGJFSA-N Asp-Asp-Ser Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O QXHVOUSPVAWEMX-ZLUOBGJFSA-N 0.000 claims description 5
ZVYYMCXVPZEAPU-CWRNSKLLSA-N Asp-Trp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@H](CC(=O)O)N)C(=O)O ZVYYMCXVPZEAPU-CWRNSKLLSA-N 0.000 claims description 5
208000007536 Thrombosis Diseases 0.000 claims description 5
230000032683 aging Effects 0.000 claims description 5
108010087924 alanylproline Proteins 0.000 claims description 5
230000008021 deposition Effects 0.000 claims description 5
201000010099 disease Diseases 0.000 claims description 5
208000015181 infectious disease Diseases 0.000 claims description 5
CGOHAEBMDSEKFB-FXQIFTODSA-N Glu-Glu-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O CGOHAEBMDSEKFB-FXQIFTODSA-N 0.000 claims description 4
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 4
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 4
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 4
208000025747 Rheumatic disease Diseases 0.000 claims description 4
125000003158 alcohol group Chemical group 0.000 claims description 4
108010021908 aspartyl-aspartyl-glutamyl-aspartic acid Proteins 0.000 claims description 4
150000007529 inorganic bases Chemical group 0.000 claims description 4
150000007530 organic bases Chemical class 0.000 claims description 4
210000003556 vascular endothelial cell Anatomy 0.000 claims description 4
KUBFPYIMAGXGBT-ACZMJKKPSA-N Gln-Ser-Ala Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O KUBFPYIMAGXGBT-ACZMJKKPSA-N 0.000 claims description 3
PBFGQTGPSKWHJA-QEJZJMRPSA-N Glu-Asp-Trp Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O PBFGQTGPSKWHJA-QEJZJMRPSA-N 0.000 claims description 3
TWVKGYNQQAUNRN-ACZMJKKPSA-N Ile-Ser Chemical compound CC[C@H](C)[C@H]([NH3+])C(=O)N[C@@H](CO)C([O-])=O TWVKGYNQQAUNRN-ACZMJKKPSA-N 0.000 claims description 3
208000026350 Inborn Genetic disease Diseases 0.000 claims description 3
230000001363 autoimmune Effects 0.000 claims description 3
208000035475 disorder Diseases 0.000 claims description 3
208000016361 genetic disease Diseases 0.000 claims description 3
210000000987 immune system Anatomy 0.000 claims description 3
230000002458 infectious effect Effects 0.000 claims description 3
125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
229940124597 therapeutic agent Drugs 0.000 claims description 3
WPWUFUBLGADILS-WDSKDSINSA-N Ala-Pro Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(O)=O WPWUFUBLGADILS-WDSKDSINSA-N 0.000 claims description 2
CGBYDGAJHSOGFQ-LPEHRKFASA-N Pro-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@@H]2CCCN2 CGBYDGAJHSOGFQ-LPEHRKFASA-N 0.000 claims description 2
229940126601 medicinal product Drugs 0.000 claims description 2
108010077112 prolyl-proline Proteins 0.000 claims description 2
230000018109 developmental process Effects 0.000 claims 13
PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims 12
150000002430 hydrocarbons Chemical group 0.000 claims 4
FRYULLIZUDQONW-IMJSIDKUSA-N Asp-Asp Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(O)=O FRYULLIZUDQONW-IMJSIDKUSA-N 0.000 claims 3
108010040443 aspartyl-aspartic acid Proteins 0.000 claims 3
VNYMOTCMNHJGTG-JBDRJPRFSA-N Ala-Ile-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O VNYMOTCMNHJGTG-JBDRJPRFSA-N 0.000 claims 1
XWFWAXPOLRTDFZ-FXQIFTODSA-N Ala-Pro-Ser Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O XWFWAXPOLRTDFZ-FXQIFTODSA-N 0.000 claims 1
KOSRFJWDECSPRO-WDSKDSINSA-N Glu-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(O)=O KOSRFJWDECSPRO-WDSKDSINSA-N 0.000 claims 1
AWJGUZSYVIVZGP-YUMQZZPRSA-N Pro-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1 AWJGUZSYVIVZGP-YUMQZZPRSA-N 0.000 claims 1
KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 claims 1
108010055341 glutamyl-glutamic acid Proteins 0.000 claims 1
108010053725 prolylvaline Proteins 0.000 claims 1
150000001875 compounds Chemical class 0.000 abstract description 3
125000001183 hydrocarbyl group Chemical group 0.000 abstract description 3
239000004475 Arginine Substances 0.000 abstract 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 1
239000000463 material Substances 0.000 abstract 1
108010002921 NDSK-II Proteins 0.000 description 50
NYPJDWWKZLNGGM-RPWUZVMVSA-N esfenvalerate Chemical compound C=1C([C@@H](C#N)OC(=O)[C@@H](C(C)C)C=2C=CC(Cl)=CC=2)=CC=CC=1OC1=CC=CC=C1 NYPJDWWKZLNGGM-RPWUZVMVSA-N 0.000 description 47
230000005012 migration Effects 0.000 description 19
238000013508 migration Methods 0.000 description 19
210000004698 lymphocyte Anatomy 0.000 description 17
210000001519 tissue Anatomy 0.000 description 15
230000000694 effects Effects 0.000 description 14
210000001616 monocyte Anatomy 0.000 description 12
108010049003 Fibrinogen Proteins 0.000 description 10
102000008946 Fibrinogen Human genes 0.000 description 10
229940012952 fibrinogen Drugs 0.000 description 10
210000002216 heart Anatomy 0.000 description 10
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 9
210000004969 inflammatory cell Anatomy 0.000 description 8
210000003462 vein Anatomy 0.000 description 8
108090000190 Thrombin Proteins 0.000 description 7
210000001367 artery Anatomy 0.000 description 7
229960004072 thrombin Drugs 0.000 description 7
238000000034 method Methods 0.000 description 6
241000699670 Mus sp. Species 0.000 description 5
230000000052 comparative effect Effects 0.000 description 5
230000000527 lymphocytic effect Effects 0.000 description 5
102000008186 Collagen Human genes 0.000 description 4
108010035532 Collagen Proteins 0.000 description 4
241000700159 Rattus Species 0.000 description 4
239000000654 additive Substances 0.000 description 4
230000000996 additive effect Effects 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
229920001436 collagen Polymers 0.000 description 4
239000011159 matrix material Substances 0.000 description 4
239000000047 product Substances 0.000 description 4
FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 3
MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 3
108010058861 Fibrin Fibrinogen Degradation Products Proteins 0.000 description 3
229960004544 cortisone Drugs 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
239000000208 fibrin degradation product Substances 0.000 description 3
238000011866 long-term treatment Methods 0.000 description 3
208000010125 myocardial infarction Diseases 0.000 description 3
230000008569 process Effects 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
208000010444 Acidosis Diseases 0.000 description 2
MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 2
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
108010036949 Cyclosporine Proteins 0.000 description 2
101800003778 Fibrinopeptide B Proteins 0.000 description 2
206010021143 Hypoxia Diseases 0.000 description 2
150000008575 L-amino acids Chemical class 0.000 description 2
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
238000011579 SCID mouse model Methods 0.000 description 2
208000027418 Wounds and injury Diseases 0.000 description 2
VJMAITQRABEEKP-UHFFFAOYSA-N [6-(phenylmethoxymethyl)-1,4-dioxan-2-yl]methyl acetate Chemical compound O1C(COC(=O)C)COCC1COCC1=CC=CC=C1 VJMAITQRABEEKP-UHFFFAOYSA-N 0.000 description 2
230000007950 acidosis Effects 0.000 description 2
208000026545 acidosis disease Diseases 0.000 description 2
230000009471 action Effects 0.000 description 2
230000004913 activation Effects 0.000 description 2
230000001464 adherent effect Effects 0.000 description 2
238000010171 animal model Methods 0.000 description 2
230000003110 anti-inflammatory effect Effects 0.000 description 2
230000023555 blood coagulation Effects 0.000 description 2
230000036772 blood pressure Effects 0.000 description 2
229960001265 ciclosporin Drugs 0.000 description 2
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 2
230000006378 damage Effects 0.000 description 2
230000003412 degenerative effect Effects 0.000 description 2
MUCZHBLJLSDCSD-UHFFFAOYSA-N diisopropyl fluorophosphate Chemical compound CC(C)OP(F)(=O)OC(C)C MUCZHBLJLSDCSD-UHFFFAOYSA-N 0.000 description 2
239000007850 fluorescent dye Substances 0.000 description 2
229960005051 fluostigmine Drugs 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
229960003444 immunosuppressant agent Drugs 0.000 description 2
239000003018 immunosuppressive agent Substances 0.000 description 2
208000014674 injury Diseases 0.000 description 2
238000003780 insertion Methods 0.000 description 2
230000037431 insertion Effects 0.000 description 2
QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 2
229910052753 mercury Inorganic materials 0.000 description 2
239000003068 molecular probe Substances 0.000 description 2
239000013642 negative control Substances 0.000 description 2
230000001717 pathogenic effect Effects 0.000 description 2
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
230000004224 protection Effects 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
239000000725 suspension Substances 0.000 description 2
230000000451 tissue damage Effects 0.000 description 2
231100000827 tissue damage Toxicity 0.000 description 2
230000004614 tumor growth Effects 0.000 description 2
IPJDHSYCSQAODE-UHFFFAOYSA-N 5-chloromethylfluorescein diacetate Chemical compound O1C(=O)C2=CC(CCl)=CC=C2C21C1=CC=C(OC(C)=O)C=C1OC1=CC(OC(=O)C)=CC=C21 IPJDHSYCSQAODE-UHFFFAOYSA-N 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
238000012935 Averaging Methods 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
206010053567 Coagulopathies Diseases 0.000 description 1
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
101800000974 Fibrinopeptide A Proteins 0.000 description 1
102400001063 Fibrinopeptide B Human genes 0.000 description 1
241000131390 Glis Species 0.000 description 1
JPHYJQHPILOKHC-ACZMJKKPSA-N Glu-Asp-Asp Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O JPHYJQHPILOKHC-ACZMJKKPSA-N 0.000 description 1
108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
206010061216 Infarction Diseases 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
206010029113 Neovascularisation Diseases 0.000 description 1
RYXPMWYHEBGTRV-UHFFFAOYSA-N Omeprazole sodium Chemical compound [Na+].N=1C2=CC(OC)=CC=C2[N-]C=1S(=O)CC1=NC=C(C)C(OC)=C1C RYXPMWYHEBGTRV-UHFFFAOYSA-N 0.000 description 1
RWCOTTLHDJWHRS-YUMQZZPRSA-N Pro-Pro Chemical compound OC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 RWCOTTLHDJWHRS-YUMQZZPRSA-N 0.000 description 1
108010094028 Prothrombin Proteins 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
241000700157 Rattus norvegicus Species 0.000 description 1
208000001647 Renal Insufficiency Diseases 0.000 description 1
208000005250 Spontaneous Fractures Diseases 0.000 description 1
102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
208000024248 Vascular System injury Diseases 0.000 description 1
208000012339 Vascular injury Diseases 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
230000001772 anti-angiogenic effect Effects 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
229960002170 azathioprine Drugs 0.000 description 1
LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
208000015294 blood coagulation disease Diseases 0.000 description 1
230000036770 blood supply Effects 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000020411 cell activation Effects 0.000 description 1
230000032823 cell division Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
230000009852 coagulant defect Effects 0.000 description 1
229960004397 cyclophosphamide Drugs 0.000 description 1
229930182912 cyclosporin Natural products 0.000 description 1
230000007547 defect Effects 0.000 description 1
239000007857 degradation product Substances 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
238000001212 derivatisation Methods 0.000 description 1
239000000975 dye Substances 0.000 description 1
230000003511 endothelial effect Effects 0.000 description 1
239000000282 fibrinogen degradation product Substances 0.000 description 1
MYRIFIVQGRMHRF-OECXYHNASA-N fibrinopeptide b Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)CNC(=O)[C@@H]1CCC(=O)N1 MYRIFIVQGRMHRF-OECXYHNASA-N 0.000 description 1
239000012634 fragment Substances 0.000 description 1
239000007789 gas Substances 0.000 description 1
208000024908 graft versus host disease Diseases 0.000 description 1
210000003714 granulocyte Anatomy 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
230000007954 hypoxia Effects 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000007574 infarction Effects 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000000302 ischemic effect Effects 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
230000003902 lesion Effects 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
239000003446 ligand Substances 0.000 description 1
238000004811 liquid chromatography Methods 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
208000030159 metabolic disease Diseases 0.000 description 1
244000000010 microbial pathogen Species 0.000 description 1
210000004165 myocardium Anatomy 0.000 description 1
230000037125 natural defense Effects 0.000 description 1
230000001009 osteoporotic effect Effects 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
108010091748 peptide A Proteins 0.000 description 1
238000010647 peptide synthesis reaction Methods 0.000 description 1
210000004976 peripheral blood cell Anatomy 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
239000012071 phase Substances 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
208000026881 post-infectious disease Diseases 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
230000009979 protective mechanism Effects 0.000 description 1
230000007026 protein scission Effects 0.000 description 1
230000006337 proteolytic cleavage Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000029058 respiratory gaseous exchange Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
230000007017 scission Effects 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
235000000891 standard diet Nutrition 0.000 description 1
230000001629 suppression Effects 0.000 description 1
238000011477 surgical intervention Methods 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
238000012360 testing method Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
230000000472 traumatic effect Effects 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
210000003606 umbilical vein Anatomy 0.000 description 1
239000004474 valine Substances 0.000 description 1
238000007631 vascular surgery Methods 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/363—Fibrinogen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/75—Fibrinogen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Proteomics, Peptides & Aminoacids (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Hematology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Cardiology (AREA)
Toxicology (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Rheumatology (AREA)
Transplantation (AREA)
Pain & Pain Management (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

BG107891A 2000-12-12 2003-06-09 П...п'иди и/или про'...ини и 'яхно'о използван... за пол"-аван... на л...кар''в...но 'р...д''во за л...-...ни... и/или про"илак'ика BG107891A (bg)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
AT20632000		2000-12-12
PCT/AT2001/000387 WO2002048180A2 (fr)	2000-12-12	2001-12-07	Peptides et/ou proteines ainsi que leur utilisation dans la fabrication d'un medicament therapeutique et/ou preventif

Publications (1)

Publication Number	Publication Date
BG107891A true BG107891A (bg)	2004-08-31

Family

ID=3689750

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG107891A BG107891A (bg)	2000-12-12	2003-06-09	П...п'иди и/или про'...ини и 'яхно'о използван... за пол"-аван... на л...кар''в...но 'р...д''во за л...-...ни... и/или про"илак'ика

Country Status (30)

Country	Link
US (4)	US7271144B2 (fr)
EP (2)	EP1586586B1 (fr)
JP (1)	JP4181874B2 (fr)
KR (1)	KR100864069B1 (fr)
CN (2)	CN101676299A (fr)
AT (2)	ATE425184T1 (fr)
AU (1)	AU2002221316A1 (fr)
BG (1)	BG107891A (fr)
BR (1)	BR0116122A (fr)
CA (1)	CA2430972C (fr)
CY (2)	CY1106108T1 (fr)
CZ (1)	CZ20031630A3 (fr)
DE (2)	DE50110182D1 (fr)
DK (2)	DK1586586T3 (fr)
EA (1)	EA005576B1 (fr)
EE (1)	EE200300283A (fr)
ES (2)	ES2323963T3 (fr)
HR (1)	HRP20030564A2 (fr)
HU (1)	HUP0401536A3 (fr)
IL (2)	IL156360A0 (fr)
MX (1)	MXPA03005218A (fr)
NO (1)	NO330767B1 (fr)
NZ (1)	NZ550619A (fr)
PL (2)	PL209419B1 (fr)
PT (2)	PT1341819E (fr)
SI (2)	SI1341819T1 (fr)
SK (1)	SK7062003A3 (fr)
WO (1)	WO2002048180A2 (fr)
YU (1)	YU53803A (fr)
ZA (1)	ZA200304545B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1586586B1 (fr)	2000-12-12	2009-03-11	Fibrex Medical Research & Development GmbH	Peptide et/ou protéines ainsi que leur utilisation dans la fabrication d'un médicament thérapeutique et/ou préventif
SI1691827T1 (sl) *	2004-06-25	2010-01-29	Fibrex Medical Res & Dev Gmbh	Uporaba peptidov, izvedenih iz Bbeta-verige ÄŤloveĹˇkega fibrinogena, za zdravljenje Ĺˇoka
FR2879604B1 (fr) *	2004-12-22	2010-08-13	Biomerieux Sa	Peptides citrullines derives de la fibrine reconnus par des auto-anticorps specifiques de la polyarthrite rhumatoide, et leurs utilisations
AT502987A1 (de) *	2005-12-23	2007-07-15	Fibrex Medical Res & Dev Gmbh	Pharmazeutische zusammensetzung zur behandlung von hämorrhagischem schock und seinen folgeerscheinungen
DK1987063T3 (da) *	2006-02-23	2010-01-04	Fibrex Medical Res & Dev Gmbh	Peptider og peptidderivater, fremstilling deraf samt deres anvendelse til fremstilling af en terapeutisk og/eller præventivt aktiv farmaceutisk sammensætning
WO2007095659A1 (fr) *	2006-02-23	2007-08-30	Fibrex Medical Research & Development Gmbh	Peptides et dérivés peptidiques, leur préparation et leur utilisation pour produire un médicament ayant une activité thérapeutique et/ou prophylactique
CN101389653A (zh)	2006-02-23	2009-03-18	菲布雷克斯医疗研究及开发有限责任公司	肽和肽衍生物以及含有它们的药物组合物
FR2900657B1 (fr) *	2006-05-03	2009-04-17	Univ Toulouse	Identification de modulateurs de l'activation des macrophages, utilisables pour le traitement de la polyarthrite rhumatoide
US8722623B2 (en)	2007-09-17	2014-05-13	University Of Maryland, Baltimore	Compositions and methods utilizing fibrin beta chain fragments
FR2908134B1 (fr) *	2007-12-04	2012-10-12	Univ Toulouse 3 Paul Sabatier	Identification de modulateurs de l'activation des macrophages, utilisables pour le traitement de la polyarthrite rhumatoide
JP5410997B2 (ja) *	2008-01-31	2014-02-05	則行川村	うつ病およびうつ状態のマーカーおよびそれを用いた検出・診断
US20090286725A1 (en) *	2008-05-15	2009-11-19	Fibrex Medical Research & Development Gmbh	Peptides and derivatives thereof, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition
US8088890B2 (en) *	2008-09-26	2012-01-03	Fibrex Medical Research & Development Gmbh	Peptides and peptidomimetic compounds, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition
WO2010043444A2 (fr) *	2008-10-15	2010-04-22	Fibrex Medical Research & Development Gmbh	Préparation pharmaceutique pour le traitement et/ou la prévention d'une lésion par ischémie/reperfusion et de ses séquelles
US20100152832A1 (en) *	2008-12-12	2010-06-17	Medtronic Vascular, Inc.	Apparatus and Methods for Treatment of Aneurysms With Fibrin Derived Peptide B-Beta
WO2013082458A1 (fr)	2011-12-02	2013-06-06	The Regents Of The University Of California	Solution de protection de reperfusion et ses utilisations
US12171802B2 (en)	2016-06-02	2024-12-24	University Of Maryland, Baltimore	Compositions for inhibiting fibrin-VLDL receptor-dependent inflammation and methods of treatment
EP3912679A1 (fr) *	2020-05-19	2021-11-24	Johann Wolfgang Goethe-Universität Frankfurt am Main	Bbeta pour le traitement de l'endothélite virale

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4927916A (en)	1984-04-23	1990-05-22	The General Hospital Corporation	Method of producing fibrin-specific monoclonal antibodies lacking fibrinogen-cross-reactivity using fibrin-specific peptides
US5965107A (en) *	1992-03-13	1999-10-12	Diatide, Inc.	Technetium-99m labeled peptides for imaging
DE19729591A1 (de) *	1997-07-10	1999-02-11	Therasorb Medizinische Systeme	Mittel zur Behandlung und/oder Prophylaxe von Mikrozirkulationsstörungen
FR2795735B1 (fr) *	1999-07-01	2001-09-07	Univ Toulouse	Derives citrullines de la fibrine et leur utilisation pour le diagnostic ou le traitement de la polyarthrite rhumatoide
EP1586586B1 (fr) *	2000-12-12	2009-03-11	Fibrex Medical Research & Development GmbH	Peptide et/ou protéines ainsi que leur utilisation dans la fabrication d'un médicament thérapeutique et/ou préventif
US7201763B2 (en) *	2001-10-24	2007-04-10	Boston Scientific Scimed, Inc.	Distal balloon waist material relief and method of manufacture

2001
- 2001-12-07 EP EP05012488A patent/EP1586586B1/fr not_active Expired - Lifetime
- 2001-12-07 PT PT01270546T patent/PT1341819E/pt unknown
- 2001-12-07 EP EP01270546A patent/EP1341819B1/fr not_active Expired - Lifetime
- 2001-12-07 YU YU53803A patent/YU53803A/sh unknown
- 2001-12-07 HU HU0401536A patent/HUP0401536A3/hu unknown
- 2001-12-07 EA EA200300678A patent/EA005576B1/ru not_active IP Right Cessation
- 2001-12-07 JP JP2002549711A patent/JP4181874B2/ja not_active Expired - Fee Related
- 2001-12-07 DK DK05012488T patent/DK1586586T3/da active
- 2001-12-07 DE DE50110182T patent/DE50110182D1/de not_active Expired - Lifetime
- 2001-12-07 EE EEP200300283A patent/EE200300283A/xx unknown
- 2001-12-07 MX MXPA03005218A patent/MXPA03005218A/es active IP Right Grant
- 2001-12-07 WO PCT/AT2001/000387 patent/WO2002048180A2/fr active IP Right Grant
- 2001-12-07 CN CN200910163553A patent/CN101676299A/zh active Pending
- 2001-12-07 SK SK706-2003A patent/SK7062003A3/sk unknown
- 2001-12-07 BR BR0116122-9A patent/BR0116122A/pt not_active Application Discontinuation
- 2001-12-07 HR HR20030564A patent/HRP20030564A2/hr not_active Application Discontinuation
- 2001-12-07 DK DK01270546T patent/DK1341819T3/da active
- 2001-12-07 SI SI200130609T patent/SI1341819T1/sl unknown
- 2001-12-07 AT AT05012488T patent/ATE425184T1/de active
- 2001-12-07 KR KR1020037007799A patent/KR100864069B1/ko not_active Expired - Fee Related
- 2001-12-07 AT AT01270546T patent/ATE329614T1/de active
- 2001-12-07 IL IL15636001A patent/IL156360A0/xx unknown
- 2001-12-07 CN CN018225993A patent/CN1518558B/zh not_active Expired - Fee Related
- 2001-12-07 NZ NZ550619A patent/NZ550619A/en unknown
- 2001-12-07 ES ES05012488T patent/ES2323963T3/es not_active Expired - Lifetime
- 2001-12-07 AU AU2002221316A patent/AU2002221316A1/en not_active Abandoned
- 2001-12-07 CZ CZ20031630A patent/CZ20031630A3/cs unknown
- 2001-12-07 PT PT05012488T patent/PT1586586E/pt unknown
- 2001-12-07 PL PL362924A patent/PL209419B1/pl not_active IP Right Cessation
- 2001-12-07 PL PL390342A patent/PL209752B1/pl not_active IP Right Cessation
- 2001-12-07 SI SI200130917T patent/SI1586586T1/sl unknown
- 2001-12-07 ES ES01270546T patent/ES2266093T3/es not_active Expired - Lifetime
- 2001-12-07 CA CA2430972A patent/CA2430972C/fr not_active Expired - Fee Related
- 2001-12-07 DE DE50114771T patent/DE50114771D1/de not_active Expired - Lifetime
2003
- 2003-06-09 IL IL156360A patent/IL156360A/en not_active IP Right Cessation
- 2003-06-09 BG BG107891A patent/BG107891A/bg unknown
- 2003-06-11 US US10/459,030 patent/US7271144B2/en not_active Expired - Fee Related
- 2003-06-12 NO NO20032656A patent/NO330767B1/no not_active IP Right Cessation
2004
- 2004-06-11 ZA ZA200304545A patent/ZA200304545B/en unknown
2006
- 2006-06-27 CY CY20061100876T patent/CY1106108T1/el unknown
- 2006-10-03 US US11/542,050 patent/US7494973B2/en not_active Expired - Lifetime
2007
- 2007-09-06 US US11/899,611 patent/US7811985B2/en not_active Expired - Fee Related
2008
- 2008-10-09 US US12/248,656 patent/US8067373B2/en not_active Expired - Fee Related
2009
- 2009-05-29 CY CY20091100574T patent/CY1109107T1/el unknown

Also Published As

Publication number	Publication date
CA2430972C (fr)	2014-08-05
US20040192596A1 (en)	2004-09-30
US7811985B2 (en)	2010-10-12
PT1586586E (pt)	2010-05-28
ES2266093T3 (es)	2007-03-01
ZA200304545B (en)	2004-09-13
ES2323963T3 (es)	2009-07-28
WO2002048180A3 (fr)	2003-01-30
PL362924A1 (en)	2004-11-02
JP2004527469A (ja)	2004-09-09
MXPA03005218A (es)	2004-12-03
NO20032656L (no)	2003-06-12
IL156360A0 (en)	2004-01-04
BR0116122A (pt)	2003-10-14
SK7062003A3 (en)	2003-11-04
US20090137464A1 (en)	2009-05-28
CN1518558A (zh)	2004-08-04
NO20032656D0 (no)	2003-06-12
US20070037749A1 (en)	2007-02-15
EP1586586B1 (fr)	2009-03-11
NZ550619A (en)	2008-06-30
SI1341819T1 (sl)	2006-10-31
EA200300678A1 (ru)	2003-10-30
PL209752B1 (pl)	2011-10-31
CY1106108T1 (el)	2011-06-08
DK1341819T3 (da)	2006-10-16
ATE329614T1 (de)	2006-07-15
WO2002048180A2 (fr)	2002-06-20
NO330767B1 (no)	2011-07-11
CN1518558B (zh)	2010-06-16
KR100864069B1 (ko)	2008-10-16
EP1586586A2 (fr)	2005-10-19
US20090088384A1 (en)	2009-04-02
US7494973B2 (en)	2009-02-24
HRP20030564A2 (en)	2005-06-30
DK1586586T3 (da)	2009-06-29
EA005576B1 (ru)	2005-04-28
EP1341819B1 (fr)	2006-06-14
US8067373B2 (en)	2011-11-29
CZ20031630A3 (cs)	2003-10-15
HUP0401536A2 (hu)	2004-11-29
HK1084400A1 (zh)	2006-07-28
DE50110182D1 (de)	2006-07-27
PT1341819E (pt)	2006-10-31
DE50114771D1 (de)	2009-04-23
KR20030060988A (ko)	2003-07-16
SI1586586T1 (sl)	2009-08-31
US7271144B2 (en)	2007-09-18
EP1341819A2 (fr)	2003-09-10
CY1109107T1 (el)	2014-07-02
YU53803A (sh)	2006-03-03
CN101676299A (zh)	2010-03-24
AU2002221316A1 (en)	2002-06-24
JP4181874B2 (ja)	2008-11-19
ATE425184T1 (de)	2009-03-15
CA2430972A1 (fr)	2002-06-20
EP1586586A3 (fr)	2006-03-29
IL156360A (en)	2012-12-31
HUP0401536A3 (en)	2008-09-29
EE200300283A (et)	2003-10-15
PL209419B1 (pl)	2011-08-31

Publication	Publication Date	Title
US7494973B2 (en)	2009-02-24	Therapeutic fibrin-derived peptides and uses thereof
AU2007219031B2 (en)	2011-11-03	Peptides and peptide derivatives as well as pharmaceutical compositions containing the same
JP2004527469A6 (ja)	2005-02-03	ペプチドおよび／またはタンパク質、並びにその治療用および／または予防用医薬成分を調製するための使用
AU2007219032B2 (en)	2011-06-09	Peptides and peptide derivatives, the production thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition
HK1084400B (en)	2009-07-03	Peptide and/or proteins and their use for the manufacture of a therapeutic and/or preventive medicament
JPH083065A (ja)	1996-01-09	肝臓障害に対する治療剤
HK1140212A (en)	2010-11-19	Peptides and/or proteins and use thereof for the production of a therapeutic and/or prophylactic pharmaceutical